{
  "report_rows": [
    {
      "kpi": "FFO as Adjusted per share (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$0.45 vs. cons $0.44",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$734M vs. cons $726M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Lab Same-Store Cash NOI growth (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~-3.5% vs. cons ~-6.0%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 FFO as Adjusted guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$1.73 (reaffirmed $1.71-$1.75 range) vs. cons $1.73 (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 Total Same-Store Cash NOI guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~0.0% (reaffirmed -1.0%/+1.0% range) vs. cons ~0.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "H2'26 quarterly FFOA run-rate / interest expense cadence",
      "prediction": "LOWER",
      "answer": "guide ~$0.42/share vs. cons ~$0.43/share (Q3-Q4 2026, reflecting June $650M note refinancing at higher rates)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.0,
  "day5_path": "FADE",
  "day5_rationale": "A modest Q2 FFOA/revenue beat and incremental Lab stabilization likely drive an initial pop, but the stock has already re-rated ~30-34% since Q1 on deal-flow (Janus IPO, Blackstone/Brookfield JVs), so much of the 'good news' is priced in. The implicit H2 interest-expense drag from refinancing the $650M 3.5% notes at materially higher current rates, plus FY guidance simply being reaffirmed rather than raised again (after the Q1 raise), gives sell-side little room to lift out-period (Q3/Q4 and FY) numbers and some reason to trim them \u2014 pulling estimates and the stock back from the day-1 pop over the following days.",
  "day5_confidence": "MEDIUM"
}